Healthcare providers may face financial penalties for information blocking under a proposed rule by the U.S. Department of Health and Human Services (HHS). The rule targets healthcare providers, who could be penalised and may face disincentives related to federal reimbursement programs. HHS is seeking public comments on the rule until January 2, 2024.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
